<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32669334</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>19</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Single-Point Mutations within the Coxsackie B Virus Receptor-Binding Site Promote Resistance against Soluble Virus Receptor Traps.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e00952-20</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00952-20</ELocationID><Abstract><AbstractText>Coxsackie B viruses (CVB) cause a wide spectrum of diseases, ranging from mild respiratory syndromes and hand, foot, and mouth disease to life-threatening conditions, such as pancreatitis, myocarditis, and encephalitis. Previously, we and others found that the soluble virus receptor trap sCAR-Fc strongly attenuates CVB3 infection in mice. In this study, we investigated whether treatment with sCAR-Fc results in development of resistance by CVB3. Two CVB3 strains (CVB3-H3 and CVB3 Nancy) were passaged in HeLa cells in the presence of sCAR-Fc. The CVB3-H3 strain did not develop resistance, whereas two populations of CVB3 Nancy mutants emerged, one with complete (CVB3<sub>M</sub>) and one with partial (CVB3<sub>K</sub>) resistance. DNA sequence alignment of the resistant virus variant CVB3<sub>M</sub> with CVB3 Nancy revealed an amino acid exchange from Asn(N) to Ser(S) at position 139 of the CVB3 capsid protein VP2 (N2139S), an amino acid predicted to be involved in the virus's interaction with its cognate receptor CAR. Insertion of the N2139S mutation into CVB3-H3 by site-directed mutagenesis promoted resistance of the engineered CVB3-H3<sub>N2139S</sub> to sCAR-Fc. Interestingly, development of resistance by CVB3-H3<sub>N2139S</sub> and the exemplarily investigated CVB3<sub>M</sub>-clone 2 (CVB3<sub>M2</sub>) against soluble CAR did not compromise the use of cellular CAR for viral infection. Infection of HeLa cells showed that sCAR-Fc resistance, however, negatively affected both virus stability and viral replication compared to that of the parental strains. These data demonstrate that during sCAR-Fc exposure, CVB3 can develop resistance against sCAR-Fc by single-amino-acid exchanges within the virus-receptor binding site, which, however, come at the expense of viral fitness.<b>IMPORTANCE</b> The emergence of resistant viruses is one of the most frequent obstacles preventing successful therapy of viral infections, representing a significant threat to human health. We investigated the emergence of resistant viruses during treatment with sCAR-Fc, a well-studied, highly effective antiviral molecule against CVB infections. Our data show the molecular aspects of resistant CVB3 mutants that arise during repetitive sCAR-Fc usage. However, drug resistance comes at the price of lower viral fitness. These results extend our knowledge of the development of resistance by coxsackieviruses and indicate potential limitations of antiviral therapy using soluble receptor molecules.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Pinkert et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pinkert</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2621-2453</Identifier><AffiliationInfo><Affiliation>Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, and Berlin Institute of Health (BIH), Institute of Biochemistry, Berlin, Germany sandra.pinkert@charite.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Centre for Cardiovascular Research), Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kopp</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, and Berlin Institute of Health (BIH), Institute of Biochemistry, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Br&#xfc;ckner</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, Department of Applied Biochemistry, Technische Universit&#xe4;t Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fechner</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, Department of Applied Biochemistry, Technische Universit&#xe4;t Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Beling</LastName><ForeName>Antje</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, and Berlin Institute of Health (BIH), Institute of Biochemistry, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Centre for Cardiovascular Research), Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011991">Receptors, Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C105941">coxsackievirus B receptor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="N">Myocarditis</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="Y">Point Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011991" MajorTopicYN="N">Receptors, Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral agents</Keyword><Keyword MajorTopicYN="N">coxsackievirus</Keyword><Keyword MajorTopicYN="N">drug resistance evolution</Keyword><Keyword MajorTopicYN="N">picornaviruses</Keyword><Keyword MajorTopicYN="N">soluble receptors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32669334</ArticleId><ArticleId IdType="pmc">PMC7495374</ArticleId><ArticleId IdType="doi">10.1128/JVI.00952-20</ArticleId><ArticleId IdType="pii">JVI.00952-20</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Melnick JL. 1996. Polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses, p 655&#x2013;712. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, vol 3 Lippincott-Raven, Philadelphia, PA.</Citation></Reference><Reference><Citation>Pauschinger M, Chandrasekharan K, Noutsias M, Kuhl U, Schwimmbeck LP, Schultheiss HP. 2004. Viral heart disease: molecular diagnosis, clinical prognosis, and treatment strategies. Med Microbiol Immunol 193:65&#x2013;69. doi:10.1007/s00430-003-0213-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-003-0213-y</ArticleId><ArticleId IdType="pubmed">14722762</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyoty H, Hiltunen M, Lonnrot M. 1998. Enterovirus infections and insulin dependent diabetes mellitus&#x2013;evidence for causality. Clin Diagn Virol 9:77&#x2013;84. doi:10.1016/s0928-0197(98)00007-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0928-0197(98)00007-5</ArticleId><ArticleId IdType="pubmed">9645988</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;Hl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, Schultheiss H-P. 2005. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 112:1965&#x2013;1970. doi:10.1161/CIRCULATIONAHA.105.548156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.105.548156</ArticleId><ArticleId IdType="pubmed">16172268</ArticleId></ArticleIdList></Reference><Reference><Citation>Racaniello VR. 2007. Picornaviridae: the viruses and their replication, p 795&#x2013;839. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, vol 1 Lippincot Williams &amp; Wilkins, Philadelphia, PA.</Citation></Reference><Reference><Citation>He Y, Chipman PR, Howitt J, Bator CM, Whitt MA, Baker TS, Kuhn RJ, Anderson CW, Freimuth P, Rossmann MG. 2001. Interaction of coxsackievirus B3 with the full length coxsackievirus-adenovirus receptor. Nat Struct Biol 8:874&#x2013;878. doi:10.1038/nsb1001-874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsb1001-874</ArticleId><ArticleId IdType="pmc">PMC4152846</ArticleId><ArticleId IdType="pubmed">11573093</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. 1997. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320&#x2013;1323. doi:10.1126/science.275.5304.1320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.275.5304.1320</ArticleId><ArticleId IdType="pubmed">9036860</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomko RP, Xu R, Philipson L. 1997. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A 94:3352&#x2013;3356. doi:10.1073/pnas.94.7.3352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.7.3352</ArticleId><ArticleId IdType="pmc">PMC20373</ArticleId><ArticleId IdType="pubmed">9096397</ArticleId></ArticleIdList></Reference><Reference><Citation>Organtini LJ, Makhov AM, Conway JF, Hafenstein S, Carson SD. 2014. Kinetic and structural analysis of coxsackievirus B3 receptor interactions and formation of the A-particle. J Virol 88:5755&#x2013;5765. doi:10.1128/JVI.00299-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00299-14</ArticleId><ArticleId IdType="pmc">PMC4019082</ArticleId><ArticleId IdType="pubmed">24623425</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Bowman VD, Mueller S, Bator CM, Bella J, Peng X, Baker TS, Wimmer E, Kuhn RJ, Rossmann MG. 2000. Interaction of the poliovirus receptor with poliovirus. Proc Natl Acad Sci U S A 97:79&#x2013;84. doi:10.1073/pnas.97.1.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.97.1.79</ArticleId><ArticleId IdType="pmc">PMC26619</ArticleId><ArticleId IdType="pubmed">10618374</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodfellow IG, Evans DJ, Blom AM, Kerrigan D, Miners JS, Morgan BP, Spiller OB. 2005. Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors. J Virol 79:12016&#x2013;12024. doi:10.1128/JVI.79.18.12016-12024.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.18.12016-12024.2005</ArticleId><ArticleId IdType="pmc">PMC1212587</ArticleId><ArticleId IdType="pubmed">16140777</ArticleId></ArticleIdList></Reference><Reference><Citation>Milstone AM, Petrella J, Sanchez MD, Mahmud M, Whitbeck JC, Bergelson JM. 2005. Interaction with coxsackievirus and adenovirus receptor, but not with decay-accelerating factor (DAF), induces A-particle formation in a DAF-binding coxsackievirus B3 isolate. J Virol 79:655&#x2013;660. doi:10.1128/JVI.79.1.655-660.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.1.655-660.2005</ArticleId><ArticleId IdType="pmc">PMC538729</ArticleId><ArticleId IdType="pubmed">15596863</ArticleId></ArticleIdList></Reference><Reference><Citation>Christiansen D, Devaux P, Reveil B, Evlashev A, Horvat B, Lamy J, Rabourdin-Combe C, Cohen JH, Gerlier D. 2000. Octamerization enables soluble CD46 receptor to neutralize measles virus in vitro and in vivo. J Virol 74:4672&#x2013;4678. doi:10.1128/jvi.74.10.4672-4678.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.74.10.4672-4678.2000</ArticleId><ArticleId IdType="pmc">PMC111988</ArticleId><ArticleId IdType="pubmed">10775604</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, Haworth KG, Decker JM, Alpert MD, Bailey CC, Neale ES Jr, Fellinger CH, Joshi VR, Fuchs SP, Martinez-Navio JM, Quinlan BD, Yao AY, Mouquet H, Gorman J, Zhang B, Poignard P, Nussenzweig MC, Burton DR, Kwong PD, Piatak M Jr, Lifson JD, Gao G, Desrosiers RC, Evans DT, Hahn BH, Ploss A, Cannon PM, Seaman MS, Farzan M. 2015. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519:87&#x2013;91. doi:10.1038/nature14264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14264</ArticleId><ArticleId IdType="pmc">PMC4352131</ArticleId><ArticleId IdType="pubmed">25707797</ArticleId></ArticleIdList></Reference><Reference><Citation>Roger C, Pozzuto T, Klopfleisch R, Kurreck J, Pinkert S, Fechner H. 2015. Expression of an engineered soluble coxsackievirus and adenovirus receptor by a dimeric AAV9 vector inhibits adenovirus infection in mice. Gene Ther 22:458&#x2013;466. doi:10.1038/gt.2015.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2015.19</ArticleId><ArticleId IdType="pubmed">25786873</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegmann C, Hochdorfer D, Lieber D, Subramanian N, Stohr D, Laib Sampaio K, Sinzger C. 2017. A derivative of platelet-derived growth factor receptor alpha binds to the trimer of human cytomegalovirus and inhibits entry into fibroblasts and endothelial cells. PLoS Pathog 13:e1006273. doi:10.1371/journal.ppat.1006273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006273</ArticleId><ArticleId IdType="pmc">PMC5389858</ArticleId><ArticleId IdType="pubmed">28403220</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkert S, Westermann D, Wang X, Klingel K, D&#xf6;Rner A, Savvatis K, Gr&#xf6;&#xdf;l T, Krohn S, Tsch&#xf6;Pe C, Zeichhardt H, Kotsch K, Weitmann K, Hoffmann W, Schultheiss H-P, Spiller OB, Poller W, Fechner H, 2009. Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor. Circulation 120:2358&#x2013;2366. doi:10.1161/CIRCULATIONAHA.108.845339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.845339</ArticleId><ArticleId IdType="pubmed">19933937</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkert S, Klingel K, Lindig V, Dorner A, Zeichhardt H, Spiller OB, Fechner H. 2011. Virus-host coevolution in a persistently coxsackievirus B3-infected cardiomyocyte cell line. J Virol 85:13409&#x2013;13419. doi:10.1128/JVI.00621-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00621-11</ArticleId><ArticleId IdType="pmc">PMC3233118</ArticleId><ArticleId IdType="pubmed">21976640</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim BK, Choi JH, Nam JH, Gil CO, Shin JO, Yun SH, Kim DK, Jeon ES. 2006. Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis. Cardiovasc Res 71:517&#x2013;526. doi:10.1016/j.cardiores.2006.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardiores.2006.05.016</ArticleId><ArticleId IdType="pubmed">16806133</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagawa B, Spiller OB, Proctor DG, Choy J, Luo H, Zhang HM, Suarez A, Yang D, McManus BM. 2004. Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice. J Infect Dis 189:1431&#x2013;1439. doi:10.1086/382598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/382598</ArticleId><ArticleId IdType="pubmed">15073680</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein EA, Pinkert S, Becher PM, Geisler A, Zeichhardt H, Klopfleisch R, Poller W, Tschope C, Lassner D, Fechner H, Kurreck J. 2015. Combination of RNA interference and virus receptor trap exerts additive antiviral activity in coxsackievirus B3-induced myocarditis in mice. J Infect Dis 211:613&#x2013;622. doi:10.1093/infdis/jiu504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu504</ArticleId><ArticleId IdType="pubmed">25193982</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkert S, Dieringer B, Diedrich S, Zeichhardt H, Kurreck J, Fechner H. 2016. Soluble coxsackie- and adenovirus receptor (sCAR-Fc); a highly efficient compound against laboratory and clinical strains of coxsackie-B-virus. Antiviral Res 136:1&#x2013;8. doi:10.1016/j.antiviral.2016.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.10.010</ArticleId><ArticleId IdType="pubmed">27773751</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E. 1992. Genetic variation and quasi-species. Curr Opin Genet Dev 2:61&#x2013;63. doi:10.1016/s0959-437x(05)80323-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0959-437x(05)80323-5</ArticleId><ArticleId IdType="pubmed">1633428</ArticleId></ArticleIdList></Reference><Reference><Citation>Burch CL, Chao L. 2000. Evolvability of an RNA virus is determined by its mutational neighbourhood. Nature 406:625&#x2013;628. doi:10.1038/35020564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35020564</ArticleId><ArticleId IdType="pubmed">10949302</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidtke M, Wutzler P, Zieger R, Riabova OB, Makarov VA. 2009. New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3. Antiviral Res 81:56&#x2013;63. doi:10.1016/j.antiviral.2008.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2008.09.002</ArticleId><ArticleId IdType="pubmed">18840470</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidtke M, Hammerschmidt E, Schuler S, Zell R, Birch-Hirschfeld E, Makarov VA, Riabova OB, Wutzler P. 2005. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment. J Antimicrob Chemother 56:648&#x2013;656. doi:10.1093/jac/dki263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dki263</ArticleId><ArticleId IdType="pubmed">16150864</ArticleId></ArticleIdList></Reference><Reference><Citation>Marlin SD, Staunton DE, Springer TA, Stratowa C, Sommergruber W, Merluzzi VJ. 1990. A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Nature 344:70&#x2013;72. doi:10.1038/344070a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/344070a0</ArticleId><ArticleId IdType="pubmed">1968231</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan G, Peters D, Racaniello VR. 1990. Poliovirus mutants resistant to neutralization with soluble cell receptors. Science 250:1596&#x2013;1599. doi:10.1126/science.2177226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2177226</ArticleId><ArticleId IdType="pubmed">2177226</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeating J, Balfe P, Clapham P, Weiss RA. 1991. Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity. J Virol 65:4777&#x2013;4785. doi:10.1128/JVI.65.9.4777-4785.1991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.65.9.4777-4785.1991</ArticleId><ArticleId IdType="pmc">PMC248935</ArticleId><ArticleId IdType="pubmed">1870202</ArticleId></ArticleIdList></Reference><Reference><Citation>Colston E, Racaniello VR. 1994. Soluble receptor-resistant poliovirus mutants identify surface and internal capsid residues that control interaction with the cell receptor. EMBO J 13:5855&#x2013;5862. doi:10.1002/j.1460-2075.1994.tb06930.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1994.tb06930.x</ArticleId><ArticleId IdType="pmc">PMC395560</ArticleId><ArticleId IdType="pubmed">7813425</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegmann C, Rothemund F, Laib Sampaio K, Adler B, Sinzger C. 2019. The N terminus of human cytomegalovirus glycoprotein O is important for binding to the cellular receptor PDGFRalpha. J Virol 93:e00138-19. doi:10.1128/JVI.00138-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00138-19</ArticleId><ArticleId IdType="pmc">PMC6532092</ArticleId><ArticleId IdType="pubmed">30894468</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson SD, Tracy S, Kaczmarek ZG, Alhazmi A, Chapman NM. 2016. Three capsid amino acids notably influence coxsackie B3 virus stability. J Gen Virol 97:60&#x2013;68. doi:10.1099/jgv.0.000319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000319</ArticleId><ArticleId IdType="pubmed">26489722</ArticleId></ArticleIdList></Reference><Reference><Citation>Borderia AV, Isakov O, Moratorio G, Henningsson R, Aguera-Gonzalez S, Organtini L, Gnadig NF, Blanc H, Alcover A, Hafenstein S, Fontes M, Shomron N, Vignuzzi M. 2015. Group selection and contribution of minority variants during virus adaptation determines virus fitness and phenotype. PLoS Pathog 11:e1004838. doi:10.1371/journal.ppat.1004838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004838</ArticleId><ArticleId IdType="pmc">PMC4420505</ArticleId><ArticleId IdType="pubmed">25941809</ArticleId></ArticleIdList></Reference><Reference><Citation>Groarke JM, Pevear DC. 1999. Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants. J Infect Dis 179:1538&#x2013;1541. doi:10.1086/314758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/314758</ArticleId><ArticleId IdType="pubmed">10228078</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkert S, Roger C, Kurreck J, Bergelson JM, Fechner H. 2016. The coxsackievirus and adenovirus receptor: glycosylation and the extracellular D2 domain are not required for coxsackievirus B3 infection. J Virol 90:5601&#x2013;5610. doi:10.1128/JVI.00315-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00315-16</ArticleId><ArticleId IdType="pmc">PMC4886794</ArticleId><ArticleId IdType="pubmed">27030267</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J, Narayanan B, Shah S, Yoder JD, Cifuente JO, Hafenstein S, Bergelson JM. 2011. Single amino acid changes in the virus capsid permit coxsackievirus B3 to bind decay-accelerating factor. J Virol 85:7436&#x2013;7443. doi:10.1128/JVI.00503-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00503-11</ArticleId><ArticleId IdType="pmc">PMC3126562</ArticleId><ArticleId IdType="pubmed">21561916</ArticleId></ArticleIdList></Reference><Reference><Citation>Zautner AE, Korner U, Henke A, Badorff C, Schmidtke M. 2003. Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection. J Virol 77:10071&#x2013;10077. doi:10.1128/jvi.77.18.10071-10077.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.77.18.10071-10077.2003</ArticleId><ArticleId IdType="pmc">PMC224569</ArticleId><ArticleId IdType="pubmed">12941917</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne CB, Shen L, Turner JR, Bergelson JM. 2007. Coxsackievirus entry across epithelial tight junctions requires occludin and the small GTPases Rab34 and Rab5. Cell Host Microbe 2:181&#x2013;192. doi:10.1016/j.chom.2007.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2007.07.003</ArticleId><ArticleId IdType="pmc">PMC2719558</ArticleId><ArticleId IdType="pubmed">18005733</ArticleId></ArticleIdList></Reference><Reference><Citation>Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM. 2008. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320:1496&#x2013;1501. doi:10.1126/science.1157535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1157535</ArticleId><ArticleId IdType="pmc">PMC2475333</ArticleId><ArticleId IdType="pubmed">18497260</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>